This site is intended for healthcare professionals
  • Home
  • /
  • Clinical trials
  • /
  • Uncategorised Disease
  • /
  • Microdose Study of Melphalan, Bortezomib and Dexam...
Clinical trial

Microdose Study of Melphalan, Bortezomib and Dexamethasone (Phase-0-MM)

Read time: 1 mins
Last updated:15th Jan 2014

The purpose of the study is to identify specific genes that are up- or downregulated in multiple myeloma patients who receive a microdose of either Melphalan (Alkeran®), Bortezomib (Velcade®) or Dexamethasone (Dexaven®). The study treatment constitutes 1% of the planned standard myeloma treatment and will be given two hours prior to standard treatment. Blood samples are taken at baseline, 15, 30, 60 and 120 minutes for microarray analysis.

Category Value
Study start date 2014-01-15

View full details